ANDA 76974, held by Fresenius Kabi USA. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 76974 (Ondansetron Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Dec 26, 2006, with 9 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron is approved for patients aged 6 months and older. Prevention of Postoperative Nausea and/or Vomiting Ondansetron injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 25, 2011 | Supplement 4Labeling | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters